Right this moment, MatTek Life Sciences and AIM Biotech introduced a strategic partnership by which the AIM Biotech portfolio shall be out there on the market by MatTek. During the last thirty years, MatTek has change into the chief within the superior cell tradition area and is regularly working to broaden its portfolio of services. The partnership with AIM Biotech permits MatTek to offer an ever extra complete suite of services to its purchasers and clients.
This contains the revolutionary organiX™ and idenTX™ microfluidic 3D tissue tradition platforms in addition to complete drug discovery analysis companies in key therapeutic areas of immuno-oncology, vascular biology, and neurobiology.
Whereas MatTek has led the sector in superior cell tradition and tissue tradition for many years with fashions comparable to EpiDerm™, and most lately EpiKidney™, these fashions have been developed as a single organ system inside an in vitro format. As researchers push the envelope on superior in vitro techniques, they’re turning into extra considering fashions which incorporate much more physiologically related options, comparable to perfusable vasculature, and even combining a number of organ techniques.
Considered one of our targets is to proceed to boost the complexity of in vitro tissue expertise and maintain bringing it nearer and nearer to in vivo human biology, and the microfluidic cell tradition platforms from AIM Biotech can do exactly that,” mentioned MatTek CEO Alex Armento. “By partnering with AIM Biotech we will extra simply add perfusable vasculature to in vitro fashions and construct ever extra physiologically related assays which assist higher predict in vivo outcomes.”
“AIM Biotech is happy to accomplice with MatTek in an effort to get our superior 3D tissue tradition platforms in addition to our intensive portfolio of application-specific steerage and companies into the arms of extra researchers from all over the world. Collectively we’re taking the initiative to mix AIM Biotech’s means to create self-assembling, immunocompetent, perfusable techniques with MatTek’s extensively validated cell tradition fashions. This may allow us to advance the event of assay-ready techniques that are simpler to make use of and can present physiological knowledge earlier within the drug improvement course of,” described AIM Biotech CEO Jim McGorry.
AIM Biotech’s Organ-on-a-Chip Tissue Tradition Platforms are actually out there on the market on MatTek’s on-line retailer.
